menu search

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potential...

November 3, 2023, 8:05 pm

In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting

New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-10...

November 2, 2023, 1:17 pm

Kura oncology and mirati therapeutics enter into clinical collaboration and supply agreement to evaluate ko-2806 and adagrasib in krasᴳ¹²ᶜ-mutated nsclc

– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in com...

November 2, 2023, 11:30 am

Us wegovy supply to expand ‘gradually': novo nordisk ceo

Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company's weight loss medications ...

November 2, 2023, 9:57 am

Agios pharmaceuticals to present broad set of clinical and translational data in rare blood disorders at 65th ash annual meeting and exposition

– Both Mitapivat dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion ...

November 2, 2023, 9:05 am

Immunic gets notice of allowance for us patent protecting treatment of relapsing ms with vidofludimus and salts

Immunic Inc (NASDAQ:IMUX) told investors it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application protec...

November 2, 2023, 8:13 am

Reviva pharmaceuticals: positive results in phase 3 but the stock is back where it started

Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg ...

November 2, 2023, 3:11 am

Get in early on china's economic recovery with this etf

The Chinese government is injecting a dose of stimulus measures to try and revive economic growth. That...

November 1, 2023, 4:49 pm

Vnq: the harsh dose of reality for reit investors has arrived (rating downgrade)

Vanguard Real Estate ETF has underperformed the S&P 500 significantly. Despite that, the battering is expected to continue. The surge in long-term bon...

October 29, 2023, 8:30 am

Acumen pharmaceuticals presents late-breaker phase 1 updates exploring novel target engagement, dosing regimen and safety findings for acu193 in early alzheimer’s disease at the 16th annual clinical t

– Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to...

October 27, 2023, 1:25 pm

Pharmadrug to acquire securedose synthetics in all-stock deal

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it will acquire all of the issued and outstanding shares of Secure...

October 27, 2023, 9:07 am

Paxmedica’s research on low dose suramin for autism spectrum disorder accepted for publication

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited...

October 26, 2023, 5:51 pm

New data from biogen’s investigational antisense oligonucleotide (aso) targeting tau shows promise for potential new generation of treatments in early alzheimer’s disease

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of ...

October 25, 2023, 2:51 pm

Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...

October 25, 2023, 9:05 am

Ambrx biopharma: potential with recently released prostate cancer data

Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. I...

October 23, 2023, 6:50 pm

Harpoon therapeutics stock soars on ‘promising' lung cancer drug results

Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that it...

October 23, 2023, 9:32 am

Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...

October 22, 2023, 6:59 pm

Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023

– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial ca...

October 22, 2023, 8:25 am

Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose...

October 21, 2023, 3:31 pm

Initial phase 1 dose escalation data of oric-114 in patients with egfr and her2 exon 20 mutations demonstrates potential best-in-class profile

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete resp...

October 21, 2023, 11:30 am


Search within

Pages Search Results: